2014 SNMMI Annual Meeting highlights research and looks to future

June 30, 2014

Reston, Va. (June 30, 2014) -- Top research from around the world and the latest advances in technology were brought together for the 2014 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in St. Louis, Mo., June 7-11. The meeting welcomed more than 5,700 physicians, technologists, physicists, scientists and exhibitors for an in-depth review of molecular imaging technologies, clinical applications, and translational and advanced research topics.

This year's meeting offered more than 100 scientific sessions, close to 750 oral presentations and more than 1,155 posters displayed in the poster hall. Educational courses covered topics including dose optimization, multimodality imaging, targeted radioisotope therapies, imaging in infection and inflammation and the status of DOTA agents. In the exhibit hall, more than150 companies showcased the latest in nuclear medicine and molecular imaging technology.

A highlight of the meeting was the SNMMI plenary session on Sunday, June 8, where lymphoma survivor, award-winning author and NBC news correspondent Jonathan Alter presented the Henry N. Wagner, Jr. Lectureship on "The Future of Patient-Centered Medicine." On Monday, June 9, Barry A. Siegel, MD, professor of radiology and medicine and chief of the Division of Nuclear Medicine at Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, received the 2014 Benedict Cassen Prize for research in nuclear medicine and presented a lecture titled, "What Have We Learned from the National Oncologic PET Registry?"

SNMMI's 2014 Image of the Year was chosen from an abstract presented by Nobuyuki Okamura, MD, PhD, of Tohoku University School of Medicine and his colleagues. The image--a PET image using a novel tracer, F-18 THK5117--demonstrated differential distributions of amyloid tracer versus tau/neurofibrillary tangle tracer in Alzheimer patients. This research sheds critical light on the pathology of Alzheimer's disease, which could help develop better diagnostic methods and effective treatments.

Also at the meeting, SNMMI held its fourth annual Patient Program, where more than 100 patients and caregivers attended sessions on advances in nuclear medicine and molecular imaging. Topics featured included colorectal cancer, prostate cancer, thyroid cancer and neuroendocrine tumors.

The 2015 SNMMI Annual Meeting heads to Baltimore, Md., June 6-10, 2015. For more information, visit http://www.snmmi.org.
About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Society of Nuclear Medicine

Related Molecular Imaging Articles from Brightsurf:

New technique offers higher resolution molecular imaging and analysis
The new approach from Northwestern Engineering could help researchers understand more complicated biomolecular interactions and characterize cells and diseases at the single-molecule level.

Molecular imaging offers insight into therapy outcomes for neuroendocrine tumor patients
A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

Non-invasive imaging method spots cancer at the molecular level
Researchers for the first time have combined a powerful microscopy technique with automated image analysis algorithms to distinguish between healthy and metastatic cancerous tissue without relying on invasive biopsies or the use of a contrast dye.

Molecular imaging suggests smokers may have impaired neuroimmune function
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.

Novel noninvasive molecular imaging for monitoring rheumatoid arthritis
A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity.

Improving molecular imaging using a deep learning approach
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed using a new deep learning approach to image reconstruction developed by researchers at Rensselaer Polytechnic Institute.

Nanoplatform developed with three molecular imaging modalities for tumor diagnosis
Nanotechnology and biotechnology are bringing us increasingly closer to personalised cancer treatment.

Study suggests molecular imaging strategy for determining molecular classifications of NSCLC
Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

New imaging technique able to watch molecular dynamics of neurodegenerative diseases
Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

Combined optical and molecular imaging could guide breast-conserving surgery
Breast-conserving surgery is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries.

Read More: Molecular Imaging News and Molecular Imaging Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.